Please select the option that best describes you:

Which PARP inhibitor do you recommend for maintenance therapy in BRCA mutated ovarian cancer after primary chemotherapy and why?  

Does germline vs somatic BRCA mutation affect your decision?



Answer from: at Community Practice
Sign in or Register to read more

Answer from: at Academic Institution
Sign in or Register to read more

Answer from: at Academic Institution
Sign in or Register to read more